NASDAQ:FBRX
Forte Biosciences Inc. Stock News
$0.601
-0.0290 (-4.60%)
At Close: May 17, 2024
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
04:01pm, Monday, 14'th Nov 2022
DALLAS--( BUSINESS WIRE )--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
08:59am, Wednesday, 13'th Jul 2022 Benzinga
Gainers
Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
04:00pm, Tuesday, 12'th Jul 2022 Benzinga
Gainers
Canoo Inc. (NASDAQ: GOEV) shares jumped 79.9% to $4.2627 after Walmart signed a definitive agreement with the company to purchase 4,500 all-electric delivery vehicles, beginning with the Life
Best Penny Stocks to Buy Today? 3 to Watch on May 3rd
01:33pm, Tuesday, 03'rd May 2022 PennyStocks
What to know about buying penny stocks on May 3rd
The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BiomX: Undervalued With Multiple Upcoming Catalysts
06:42pm, Wednesday, 06'th Oct 2021
BiomX: Undervalued With Multiple Upcoming Catalysts
Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of
FBRX Stock: 82.3% Decrease Explanation
08:47pm, Saturday, 04'th Sep 2021
The stock price of Forte Biosciences, Inc. (NASDAQ: FBRX) fell by 82.3% yesterday. This is why it happened.
LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.
Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate
06:19pm, Friday, 03'rd Sep 2021
Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.
Why Forte Biosciences Stock Is Down Over 80% Today
02:31pm, Friday, 03'rd Sep 2021
Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are ap
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX
02:14pm, Friday, 03'rd Sep 2021
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).
Why Forte Biosciences Stock Is Imploding Today
11:21am, Friday, 03'rd Sep 2021
The company announced dismal results from a phase 2 study of its only pipeline candidate.
Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment
07:21am, Friday, 03'rd Sep 2021
Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its le
Forte Biosciences Just Plummeted 80%: Here's Why
05:47pm, Thursday, 02'nd Sep 2021
A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:01pm, Monday, 12'th Jul 2021
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award a